People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kitov Pharma Ltd. | — | Pharmaceuticals | Series A | $42.6M | $23.2M | 2023 |
| Remix Therapeutics, Inc. | — | Biotechnology | Series A | $13.7M | $92.9M | 2023 |
Robert Gagnon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Gagnon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Bitterman | 1 | 15 |
| Peter Smith | 1 | 9 |
| Eric Rowinsky | 1 | 4 |
| Jeff Goater | 1 | 4 |
| Avraham Ben-Tzvi | 1 | 3 |
| Michael Rome | 1 | 3 |
| Matthew Patterson | 1 | 3 |
| Yael Margolin | 1 | 2 |
| Bertrand Liang | 1 | 2 |
| Isaac Israel | 1 | 2 |
| Ori Hershkovitz | 1 | 2 |
| Steven Steinberg | 1 | 2 |
| Simcha Rock | 1 | 1 |
| Suzana Nahum-Zilberberg | 1 | 1 |
| Lior Fhima | 1 | 1 |
| Hadas Reuveni | 1 | 1 |
| Gil Efron | 1 | 1 |
| Scott Biller | 1 | 1 |
| Ido Agmon | 1 | 1 |
| Fabien Sebille | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.